These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 11132040

  • 1. Pathogenetic concepts of membranous glomerulopathy (MGN).
    Kerjaschki D.
    J Nephrol; 2000; 13 Suppl 3():S96-100. PubMed ID: 11132040
    [Abstract] [Full Text] [Related]

  • 2. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis).
    Kerjaschki D, Neale TJ.
    J Am Soc Nephrol; 1996 Dec; 7(12):2518-26. PubMed ID: 8989729
    [Abstract] [Full Text] [Related]

  • 3. Megalin/GP330 and pathogenetic concepts of membranous glomerulopathy (MGN).
    Kerjaschki D.
    Kidney Blood Press Res; 2000 Dec; 23(3-5):163-6. PubMed ID: 11031710
    [No Abstract] [Full Text] [Related]

  • 4. Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis.
    Susani M, Schulze M, Exner M, Kerjaschki D.
    Am J Pathol; 1994 Apr; 144(4):807-19. PubMed ID: 8160779
    [Abstract] [Full Text] [Related]

  • 5. Differential capacity of anti-RAP and anti-megalin antibodies to produce progressive passive Heymann nephritis - implications for the pathogenesis of idiopathic human membranous glomerulonephritis.
    Makker SP, Tramontano A.
    J Pathol; 2006 Nov; 210(3):282-7. PubMed ID: 16981232
    [Abstract] [Full Text] [Related]

  • 6. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.
    Neale TJ, Ojha PP, Exner M, Poczewski H, Rüger B, Witztum JL, Davis P, Kerjaschki D.
    J Clin Invest; 1994 Oct; 94(4):1577-84. PubMed ID: 7929834
    [Abstract] [Full Text] [Related]

  • 7. Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy.
    Makker SP, Kanalas JJ.
    J Immunol; 1989 May 15; 142(10):3406-10. PubMed ID: 2654289
    [Abstract] [Full Text] [Related]

  • 8. [The immune complex pathogenesis of experimental membranous glomerulopathy (Heymann nephritis) and its significance in human glomerular disease].
    Kerjaschki D.
    Verh Dtsch Ges Pathol; 1989 May 15; 73():24-35. PubMed ID: 2482609
    [Abstract] [Full Text] [Related]

  • 9. [Molecular analysis of experimental membranous glomerulonephritis (Heymann nephritis)].
    Kerjaschki D.
    Verh Dtsch Ges Pathol; 1996 May 15; 80():139-47. PubMed ID: 9064996
    [Abstract] [Full Text] [Related]

  • 10. [Molecular pathogenesis of experimental membraneous glomerulonephritis (Heymann nephritis)].
    Kerjaschki D.
    Pathologe; 1996 Jul 15; 17(4):262-8. PubMed ID: 8927592
    [Abstract] [Full Text] [Related]

  • 11. Increased expression of cytoplasmic tail-containing form of gp600/megalin in active Heymann nephritis.
    Oleinikov AV, Makker SP.
    J Pathol; 2000 Oct 15; 192(2):251-6. PubMed ID: 11004703
    [Abstract] [Full Text] [Related]

  • 12. Involvement of an antigen distinct from the Heymann antigen in membranous glomerulonephritis in the mouse.
    Assmann KJ, Ronco P, Tangelder MM, Lange WP, Verroust P, Koene RA.
    Lab Invest; 1989 Jan 15; 60(1):138-46. PubMed ID: 2642986
    [Abstract] [Full Text] [Related]

  • 13. Heymann nephritis: a model of human membranous glomerulopathy. A study of the role of additional antigens.
    van Leer EH, Ronco P, Verroust P, de Roo GM, Hoedemaeker PJ, de Heer E.
    Nephrol Dial Transplant; 1992 Jan 15; 7 Suppl 1():1-8. PubMed ID: 1362800
    [No Abstract] [Full Text] [Related]

  • 14. Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology.
    Ronco P, Allegri L, Brianti E, Chatelet F, Van Leer EH, Verroust P.
    Appl Pathol; 1989 Jan 15; 7(2):85-98. PubMed ID: 2567175
    [Abstract] [Full Text] [Related]

  • 15. Membranous nephropathy. Insights from Heymann nephritis.
    Cavallo T.
    Am J Pathol; 1994 Apr 15; 144(4):651-8. PubMed ID: 8160766
    [No Abstract] [Full Text] [Related]

  • 16. Induction of Heymann nephritis with a gp330/megalin fusion protein.
    Raychowdhury R, Zheng G, Brown D, McCluskey RT.
    Am J Pathol; 1996 May 15; 148(5):1613-23. PubMed ID: 8623929
    [Abstract] [Full Text] [Related]

  • 17. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization.
    Ronco P, Debiec H.
    J Am Soc Nephrol; 2005 May 15; 16(5):1205-13. PubMed ID: 15800120
    [Abstract] [Full Text] [Related]

  • 18. [Etiopathogenesis of membranous nephropathy: is there a correlation between experimental and human pathology?].
    Allegri L, Celendo MT, Savazzi G, Garini G, Carnevali ML.
    Ann Ital Med Int; 1989 May 15; 4(4):386-95. PubMed ID: 2487793
    [Abstract] [Full Text] [Related]

  • 19. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro.
    Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, Li LS, Liu ZH.
    Kidney Int; 2010 Jun 15; 77(11):974-88. PubMed ID: 20375980
    [Abstract] [Full Text] [Related]

  • 20. Cytochrome P450 2B1 mediates complement-dependent sublytic injury in a model of membranous nephropathy.
    Liu H, Tian N, Arany I, Bigler SA, Waxman DJ, Shah SV, Baliga R.
    J Biol Chem; 2010 Dec 24; 285(52):40901-10. PubMed ID: 20947506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.